Visceral leishmaniasis, which is also known as Kala-Azar, is one of the most severely
neglected tropical diseases recognized by the World Health Organization (WHO). The threat …

Currently, there is no licensed vaccine to protect against human visceral leishmaniasis (VL),
a potentially fatal disease caused by infection with Leishmania parasites. In the current …

Infectious diseases like leishmaniasis, malaria, HIV, tuberculosis, leprosy and filariasis are
responsible for an immense burden on public health systems. Among these, leishmaniasis …

Visceral leishmaniasis (VL) is referred to as the most severe and fatal type of leishmaniasis
basically caused by Leishmania donovani and L. infantum. The most effective method for …

Leishmania donovani surface glycoprotein 63 (GP63) is a major virulence factor involved in
parasite escape and immune evasion. In this study, we generated virus-like particles (VLPs) …

Antigenic inefficacy to induce robust immune responses and durable memory are major
causes of constantly failing prophylactic approaches in leishmaniasis. Here, we determine …

GP63 or leishmanolysin is the major surface protease of Leishmania spp. involved in
parasite virulence and host cell interaction. As such, GP63 is a potential target of eventual …

Visceral leishmaniasis (VL) caused by Leishmania donovani is a life-threatening disease
involving uncontrolled parasitization of vital organs. Drugs to treat leishmaniasis have one or …

Leishmania, an intracellular protozoa parasite, is the causative agent of a group of diseases
called leishmaniasis. Clinical manifestations of leishmaniasis range from localized, self …

Significant information indicates that future investigations on Toxoplasma vaccine
development have to include adjuvants for enhancing protective immunity against …